Breaking News Instant updates and real-time market news.

FDC

First Data

$17.83

-0.18 (-1.00%)

, UNP

Union Pacific

$148.64

0.02 (0.01%)

18:01
11/14/18
11/14
18:01
11/14/18
18:01

Lone Pine adds Union Pacific, exits stake in Booking in Q3

Stephen Mandel's Lone Pine Capital disclosed in an SEC filing its holdings as of September 30, 2018. Lone Pine's three new buys during the third quarter included, by size of previous position, First Data (FDC), Union Pacific (UNP), and NIO Inc. The fund exited six positions during the quarter, including by size of previous position Booking (BKNG), Dollar Tree (DLTR), SBA Communications (SBAC), Square (SQ), and Mohawk Industries (MHK). Lone Pine increased its stake in 13 holdings, including by size of previous position Alibaba (BABA), Adobe (ADBE), Microsoft (MSFT), Alphabet Class C (GOOG), and Canadian Pacific Railway (CP). The fund reduced its stake in eight holdings, including by size of preivous position UnitedHealth (UNH), CSX Corp. (CSX), FleetCor Technologies (FLT), MercadoLibre (MLI), and Amazon.com (AMZN). Lone Pine's top holdings as of September 30, 2018, were Alibaba, Microsoft, Adobe, Activision Blizzard (ATVI), and Iqvia Holdings (IQV).

FDC

First Data

$17.83

-0.18 (-1.00%)

UNP

Union Pacific

$148.64

0.02 (0.01%)

BKNG

Booking Holdings

$1,887.69

-22.13 (-1.16%)

DLTR

Dollar Tree

$85.50

-1.52 (-1.75%)

SBAC

SBA Communications

$172.04

-0.46 (-0.27%)

SQ

Square

$69.85

-1.96 (-2.73%)

MHK

Mohawk

$121.31

-1.95 (-1.58%)

BABA

Alibaba

$150.55

3.72 (2.53%)

ADBE

Adobe

$235.10

-3.75 (-1.57%)

MSFT

Microsoft

$105.00

-1.47 (-1.38%)

GOOG

Alphabet

$1,043.53

7.2 (0.69%)

CP

Canadian Pacific

$206.35

-0.94 (-0.45%)

UNH

UnitedHealth

$264.95

-4.49 (-1.67%)

CSX

CSX

$70.48

0.17 (0.24%)

FLT

FleetCor

$190.96

-3.61 (-1.86%)

MLI

Mueller Industries

$24.82

-0.07 (-0.28%)

AMZN

Amazon.com

$1,599.16

-32.52 (-1.99%)

ATVI

Activision Blizzard

$51.61

-0.93 (-1.77%)

IQV

Iqvia

$117.33

-2.305 (-1.93%)

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 26

    Nov

  • 28

    Nov

  • 28

    Nov

  • 28

    Nov

  • 04

    Dec

  • 12

    Dec

  • 18

    Dec

  • 03

    Mar

FDC First Data
$17.83

-0.18 (-1.00%)

11/14/18
LEHM
11/14/18
INITIATION
Target $24
LEHM
Overweight
First Data initiated with an Overweight at Barclays
Barclays analyst Ramsey El-Assal initiated First Data with an Overweight and $24 price target.
11/14/18
LEHM
11/14/18
INITIATION
LEHM
Overweight
Barclays initiates coverage of U.S. payment processors with PayPal as top pick
As noted earlier, Barclays analyst Ramsey El-Assal initiated a group of 20 U.S. companies in the Payments, Processing, and related IT Services sector with Overweight-rated PayPal (PYPL) as his Top Pick. The analyst cites the company's "100% exposure to high-growth digital channels" along with its "clean balance sheet substantial cash position" that bring it a "strategic opportunity. El-Assal is also particularly positive on Overweight-rated WorldPay (WP) based on its strong growth potential from its exposure to "tech-enabled channels" and merger synergies, FirstData (FDC) based on the accelerating growth of its merchant channels, and Square (SQ)," whose Subscription & Services segment is blurring the lines between Payments and software". The analyst contends that the extent of being "tech-enabled" is a key differentiator in the Payments industry, assigning an Overweight rating to Alliance Data Systems (ADS), ADP (ADP), Cardtronics (CATM), Fidelity National (FIS), First Data (FDC), Fiserv (FISV), Fleetcor Technologies (FLT), Global Payments (GPN), Green Dot (GDOT), Mastercard (MA), Total System Services (TSS), Visa (V), and WEX Inc (WEX). El-Assal assigns Equal-weight ratings to EVO Payments (EVOP) and Paychex (PAYX), stating that while the companies are "solid performers" in the space, their valuation is seen as more balanced. The analyst rates MoneyGram (MGI) and Western Union (WU) at Underweight, saying that the former will struggle to re-ignite positive growth as the costs associated with regulatory scrutiny weigh on its profits and the latter will be challenged by "periodic pricing pressure eroding margins over a long period of time."
11/08/18
SUSQ
11/08/18
DOWNGRADE
Target $77
SUSQ
Neutral
Square downgraded to Neutral on valuation, CFO vacancy at Susquehanna
As reported previously, Susquehanna analyst James Friedman downgraded Square (SQ) to Neutral from Positive. The analyst cited valuation and the lack of a CFO at the company. While he sees Square taking about ten billion of cumulative revenue share from incumbent merchant acquirers, ISOs and ISVs, he would await a better re-entry point pending management visibility, Friedman tells investors. In the meantime, Friedman suggests investors look at First Data (FDC) instead, stating that Clover is generally performing as well as Square's payments products while the stock's discount to Square "seems compelling." Friedman maintained his $77 price target on Square shares.
11/06/18
COWN
11/06/18
NO CHANGE
Target $28
COWN
Outperform
First Data weakness a buying opportunity, says Cowen
Cowen analyst George Mihalos recommended investors take advantage of the overdone weakness in First Data shares. He expects the stock to recoup most of its downward move over the near-term, citing the reset of its GBS growth expectations, on-track deleveraging, and current valuation. Mihalos has an Outperform rating and $28 price target on First Data shares.
UNP Union Pacific
$148.64

0.02 (0.01%)

10/26/18
TDSI
10/26/18
DOWNGRADE
TDSI
Hold
Union Pacific downgraded to Hold from Buy at TD Securities
10/22/18
MSCO
10/22/18
DOWNGRADE
MSCO
Underweight
Union Pacific downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Ravi Shanker said he sees downside risk to consensus in 2019 across virtually the entire freight transportation group and trimmed his estimates across the board by about 2%, on average, for FY19-21 in anticipation of slowing demand trends. The analyst, who reduced his industry view to Cautious, downgraded Union Pacific to Underweight from Equal Weight.
10/24/18
10/24/18
UPGRADE
Target $190

Buy
Norfolk Southern upgraded to Buy on operating plan overhaul at Loop Capital
As previously reported, Loop Capital analyst Rick Paterson upgraded Norfolk Southern (NSC) to Buy from Hold after the company announced a process to overhaul its operating plan with "elements of PSR that are complementary to our strategy." A retooled operating plan is "necessary and long overdue," said Paterson, who also cites the recent pullback in the stock for his rating change. The analyst, who contends that Union Pacific (UNP) seems to be embracing Precision Scheduled Railroading more than Norfolk Southern, said "the debate now is whether 'PSR-Lite' is even feasible," calling the two railroads "giant test cases" of that question. Paterson raised his price target on Norfolk shares to $190 from $179.
10/26/18
TDSI
10/26/18
DOWNGRADE
Target $160
TDSI
Hold
Union Pacific downgraded to Hold on pricing at TD Securities
As previously reported, TD Securities downgraded Union Pacific to Hold from Buy and trimmed its price target to $160 from $170. Analyst Cherilyn Radbourne said Union Pacific's core price only increased 1.75% year-over-year, slightly down versus 2% in 1H 2018, and core only rose 2.75%, which was at the low-end of the 1H 2018 range of 2.75%-3%. Radbourne is concerned that pricing is not firing on all "cylinders," and volume growth is out of management's control.
BKNG Booking Holdings
$1,887.69

-22.13 (-1.16%)

11/06/18
MSCO
11/06/18
NO CHANGE
Target $2100
MSCO
Overweight
Booking Q3 results, Q4 outlook illustrate 'multiple levers,' says Morgan Stanley
Morgan Stanley analyst Brian Nowak said Booking Holdings' Q3 room nights growth being 200bp better than expected and its Q4 guidance, with the top end of room nights growth being 100bp better than expected, speak to the multiple levers the company has to pull. He is particularly bullish about the percentage of room nights coming from direct channels increasing year-over-year and the fact that direct traffic remains the largest source of new customer growth. Nowak keeps an Overweight rating and $2,100 price target on Booking shares.
11/06/18
DADA
11/06/18
NO CHANGE
Target $2000
DADA
Neutral
Booking Holdings price target nudged higher to $2,000 at DA Davidson
DA Davidson analyst Tome White raised his price target on Booking Holdings to $2,000 from $1,980 after its "strong" Q3 top-line beat and a 1% EBITDA upside, saying the 12% growth in gross bookings was also above his 5% estimate. The analyst notes however that the performance was also supported by the "later summer peak travel and higher growth from paid marketing channels," adding that the management is also prepared to "tolerate margin compression" to achieve above-industry growth rate in 2019. White also keeps his Neutral rating on Booking Holdings, noting its 20-times forward earnings valuation multiple.
11/06/18
FBCO
11/06/18
NO CHANGE
Target $2240
FBCO
Outperform
Booking Holdings price target raised to $2,240 from $2,100 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Booking Holdings to $2,240 from $2,100 following quarterly results. The analyst reiterates an Outperform rating on the shares.
11/06/18
SUSQ
11/06/18
NO CHANGE
Target $2300
SUSQ
Positive
Booking Holdings price target raised to $2,300 from $2,200 at Susquehanna
Susquehanna analyst Shyam Patil raised his price target on Booking Holdings to $2,300 from $2,200 following its Q3 results. The analyst likes its secular opportunity to penetrate hotels and alternative accommodations room nights. He believes the room night growth acceleration will ease fears around perpetual growth deceleration. Patil reiterated his Positive rating on Booking Holdings shares.
DLTR Dollar Tree
$85.50

-1.52 (-1.75%)

10/16/18
BUCK
10/16/18
NO CHANGE
Target $92
BUCK
Neutral
Buckingham reiterates Neutral on Dollar Tree as potential activism heightens
Buckingham analyst Bob Summers reiterates a Neutral rating and $92 price target on Dollar Tree shares as speculation surrounding potential activism heightens as an unconfirmed NY Post article claims Carl Icahn has established a position in the name. The NY Post article represents the pinnacle of the "activism" discussions recently surrounding the stock, the analyst notes, highlighting that that he has no direct or indirect knowledge of Carl Icahn building a position. Nonetheless, if he had to hypothesize about potential suggestions made to management, it would include spinning Family Dollar, aggressively purge the under-performing stores, and accelerate annual renovations. While there very well may be a consensus on how to go about improving the store base, Summers believes management does not have the same sense of panic or urgency.
10/17/18
KEYB
10/17/18
NO CHANGE
Target $108
KEYB
Overweight
Dollar Tree price target lowered to $108 from $115 at KeyBanc
KeyBanc analyst Bradley Thomas lowered his price target for Dollar Tree to $108 from $115, while reiterating an Overweight rating on the stock. The analyst notes that the NY Post reported that Carl Icahn is building a stake in Dollar Tree, and argues that an activist stake raises potential for a Family Dollar divestiture. Overall, Thomas believes Family Dollar trends may still be challenged and sees China tariffs as a threat to 2019 margins, but things a good degree of these risks are priced in at current levels.
10/17/18
WELS
10/17/18
NO CHANGE
Target $104
WELS
Outperform
Survey shows pressing need of ramp investment or sell Family Dollar, says Wells Fargo
Wells Fargo analyst Edward Kelly notes The New York Post reported that Carl Icahn is building a significant stake in Dollar Tree (DLTR), which could be clear opportunity to unlock value. The analyst believes Dollar Tree remains materially undervalued, but is in desperate need of change. Family Dollar looks to be suffering from underinvestment and execution issues, and his new proprietary work suggests there is a pressing need to either ramp investment to better compete with Dollar General (DG) or sell. The analyst argues that the core is a good business, but breaking the buck represents a compelling opportunity to extend growth and enhance profitability. He reiterates an Outperform rating and $104 price target on Dollar Tree's shares.
11/14/18
CLVD
11/14/18
NO CHANGE
CLVD
Neutral
Dollar Tree's Family Dollar Q3 comps appear below consensus, says Cleveland
Cleveland Research analyst Scott Bender's checks indicate Family Dollar Q3 comps appear soft versus Q2 and below Street expectations. Feedback continues to point to poor store conditions and execution as primary factors, the analyst wrote in a note to investors. Bender said feedback on Dollar Tree performance continues to be largely positive, which could act as an offset.
SBAC SBA Communications
$172.04

-0.46 (-0.27%)

08/01/18
DBAB
08/01/18
NO CHANGE
Target $169
DBAB
Buy
American Tower price target raised to $169 from $155 at Deutsche Bank
Deutsche Bank analyst Matthew Niknam raised his price target for American Tower (AMT) to $169 saying he came out of the Q2 Tower earnings reports increasingly positive. The analyst sees "very strong" core trends in the U.S. and Latin America. Commentary from the Tower companies indicates that all four national carriers are spending at an elevated clip, Niknam tells investors in a research note. The analyst keeps a Buy rating on American Tower. He also raised his price target for Hold-rated SBA Communications (SBAC) to $183 from $170.
07/30/18
MSCO
07/30/18
NO CHANGE
MSCO
Overweight
Survey of tower owners bodes well for tower stocks, says Morgan Stanley
Morgan Stanley analyst Simon Flannery said the firm's survey of 20 private tower owners points to solid leasing trends and robust demand, leading him to reiterate his Overweight ratings on American Tower (AMT) and SBA Communications (SBAC) ahead of them reporting earnings this week. Those surveyed expect momentum to continue, which he believes bodes well for second half organic growth acceleration into 2019, Flannery tells investors. He also has an Overweight rating on Crown Castle (CCI).
10/31/18
SBSH
10/31/18
UPGRADE
Target $187
SBSH
Buy
SBA Communications upgraded to Buy from Neutral at Citi
Citi analyst Michael Rollins upgraded SBA Communications (SBAC) to Buy and raised his price target for the shares to $187 from $175. American Tower's (AMT) commentary was encouraging for site leasing activity heading into 2019, and SBA is positively levered to improving domestic fundamentals, Rollins tells investors in a research note. He views SBA's valuation as "relatively attractive" and believes the company has "positive strategic optionality."
10/31/18
SBSH
10/31/18
DOWNGRADE
Target $176
SBSH
Neutral
American Tower downgraded to Neutral from Buy at Citi
Citi analyst Michael Rollins downgraded American Tower (AMT) to Neutral while raising his price target for the shares to $176 from $161. The analyst remains positive on American Tower's fundamental outlook and capital allocation strategy, but believes the recent share price strength is "better compensating shareholders for domestic business improvements and a significant portion of the retained value within its India operations." Rollins coupled the downgrade with an upgrade of SBA Communications (SBAC) to Buy.
SQ Square
$69.85

-1.96 (-2.73%)

11/08/18
RHCO
11/08/18
NO CHANGE
Target $84
RHCO
Hold
Square price target raised to $84 from $74 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on Square to $84 after its Q3 earnings beat while also raising his FY18 EPS view by 9c to 51c. The analyst notes that the company's "ecosystem value proposition is increasingly resonating with a broad swath of small-to-medium business and consumers" as demonstrated by another quarter of accelerating revenue growth. Jeffrey keeps his Hold rating on Square however, stating that its valuation already discounts much of the forecasted growth.
11/08/18
11/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Square (SQ) downgraded to Neutral from Positive at Susquehanna analyst James Friedman citing valuation and the lack of a CFO at the company. 2. Landstar System (LSTR) downgraded to Neutral from Buy at Goldman Sachs and to Sector Weight from Overweight at KeyBanc. 3. Dean Foods (DF) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying he believes the company's cost savings opportunity is significant enough to more than offset secular headwinds. 4. Ctrip (CTRP) downgraded to Neutral from Outperform at Credit Suisse, to Neutral from Buy at Citi, to Underperform from Outperform at CLSA, and to Hold from Buy at China Renaissance. 5. CDK Global (CDK) downgraded to Market Perform from Outperform at Wells Fargo with analyst Timothy Willi saying he believes that CDK faces a variety of headwinds during FY19 that will likely limit upside in the shares despite the discounted valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
LEHM
11/14/18
INITIATION
Target $96
LEHM
Overweight
Square initiated with an Overweight at Barclays
Barclays analyst Ramsey El-Assal initiated Square with an Overweight and $96 price target.
MHK Mohawk
$121.31

-1.95 (-1.58%)

10/29/18
WELS
10/29/18
NO CHANGE
Target $130
WELS
Market Perform
Mohawk price target lowered to $130 from $195 at Wells Fargo
Wells Fargo lowered its price target for Mohawk to $130 from $195 as this quarter's uncertainty creates significant uncertainty for the foreseeable future. The firm reiterates a Market Perform rating on the shares.
10/29/18
STFL
10/29/18
DOWNGRADE
Target $120
STFL
Hold
Mohawk downgraded to Hold from Buy at Stifel
Stifel analyst John Baugh downgraded Mohawk to Hold from Buy and lowered his price target on the shares to $120 from $210, stating that the company's Q3 results and next two quarters' guidance sets expectations for 2019 materially lower. While some of the factors that have driven Mohawk's margin compression in 2018 should subside going forward, the deterioration has been far worse than his previous view, Baugh added. Though he expects the stock to bottom around current levels, he does not see it as likely to rise for several quarters until margins stabilize.
10/29/18
10/29/18
DOWNGRADE

Neutral
Mohawk downgraded to Neutral following quarterly results at Credit Suisse
As previously reported, Credit Suisse analyst Susan Maklari downgraded Mohawk to Neutral from Outperform following Q3 results below expectations and a lower Q4 guide. The analyst looks for pressures to persist as Mohawk works through production delays, price/cost headwinds, and weakening global demand.
10/29/18
RHCO
10/29/18
NO CHANGE
Target $135
RHCO
Buy
Mohawk price target lowered to $135 from $270 at SunTrust
SunTrust analyst Keith Hughes lowers his price target on Mohawk to $135 after its Q3 earnings miss that was "way below expectations" and produced a 24% drop in the "already beaten up stock". The analyst notes that the "softening demand" has "exacerbated the production takedown impact", while the company's North America sales mix has also been hurt by the "limited price realization". Hughes also lowers his FY19 EPS view to $12 from $16 but keeps his Buy rating, suggesting that investors may be too bearish given the management's track record of outperformance and the company's long term competitive position.
BABA Alibaba
$150.55

3.72 (2.53%)

11/13/18
MKMP
11/13/18
NO CHANGE
Target $245
MKMP
Buy
Alibaba price target lowered to $245 from $270 at MKM Partners
MKM Partners analyst Rob Sanderson lowered his price target on Alibaba to $245, saying the bulk of his revision comes from the "lower profit from the core commerce segment as management postpones monetization efforts and braces for a possible economic slow-down". The analyst also points to the perceived "desperation" of the Chinese central bank in setting a 30% target for private enterprise loans as part of the banking system's total lending. Longer term, Sanderson keeps his Buy rating on Alibaba based on his confidence that the slowing economy will create separation for market leaders and that the company's recent execution appears to be better than in the last slowdown.
11/12/18
RHCO
11/12/18
NO CHANGE
Target $180
RHCO
Buy
Alibaba's Singles Day GMV growth was 'impressive', says SunTrust
SunTrust analyst Youssef Squali kept his Buy rating and $180 price target on Alibaba after its Singles Day result of $30.8B in gross merchandise value, highlighted by the "continued healthy consumption and rising middle class in and around China" as well as the "pervasiveness" of its ecosystem. The analyst notes that the 27% GMV increase was particularly impressive amid concerns of the macro headwinds and also points to a 40% increase in consumers who made purchases from international brands as well as the 23% increase in the delivery orders from Alibaba's Cainiao logistics network.
11/12/18
OPCO
11/12/18
NO CHANGE
OPCO
Outperform
Alibaba Singles Day growth deceleration suggests weaker macro environment, says Oppenheimer
Oppenheimer analyst Jason Helfstein notes that Alibaba's (BABA) 2018 Singles Day annual growth dropped to +27% year over year versus +39% in 2017, which he believes suggests a weaker macro environment in China, on top of the law of large numbers. The analyst also highlights that Starbucks (SBUX) participated in Double 11 for the first time. Overall, Helfstein continues to see Alibaba's ecosystem evolving with new elements, namely New Retail, Local Services and Travel. Going forward, he expects GMV growth will become more reliant on the cooperation and synergies between different channels and services. The analyst has an Outperform rating on Alibaba's shares.
11/12/18
LEHM
11/12/18
NO CHANGE
Target $195
LEHM
Overweight
Alibaba Singles' Day hits high-end of estimates, says Barclays
Barclays analyst Gregory Zhao says Alibaba's total gross merchandise volume of CNY 213.5B from the Singles' Day promotion, up 27% year-over-year, hit the high-end of his estimates. The performance came in ahead of buy-side expectations, which the analyst thinks were around low- to mid-20s. The "solid" result reaffirms the strong demand from Chinese consumers and also demonstrates Alibaba ecosystem's "strong power in the organization of such a large-scale social production," Zhao tells investors in a research note. He reiterates an Overweight rating on the shares with a $195 price target.
ADBE Adobe
$235.10

-3.75 (-1.57%)

10/19/18
WEDB
10/19/18
INITIATION
Target $270
WEDB
Neutral
Adobe initiated with a Neutral at Wedbush
Wedbush analyst Daniel Ives initiated Adobe Systems with a Neutral rating and $270 price target, telling investors in a research note that while he is very positive on the company's market opportunity over the next few years and believe ARPU expansion and more price increases could be on the horizon and represent positive growth catalysts, in the near term he feels that the risk/reward on shares at current levels is relatively balanced.
10/18/18
WEDB
10/18/18
INITIATION
WEDB
Neutral
Adobe initiated with a Neutral at Wedbush
10/16/18
ADAM
10/16/18
NO CHANGE
Target $290
ADAM
Buy
Canaccord says 'stick with a winner' after Adobe's favorable guidance
Noting that investors were nervous during yesterday's session as they worried that Adobe's weakness meant that "somebody knows something" negative was about to come, Canaccord analyst Richard Davis said that it turned out instead that Adobe announced "several compelling upgrades" and issued guidance that was as good or better than consensus. In a note entitled "When things go well, you stick with a winner," Davis said that he has raised his estimates slightly following Adobe's update and strongly believes the stock should be in a large cap growth portfolio. He keeps a Buy rating and $290 price target on Adobe shares.
10/16/18
PIPR
10/16/18
NO CHANGE
Target $310
PIPR
Overweight
Adobe remains a top pick at Piper Jaffray
Piper Jaffray analyst Alex Zukin says Adobe Systems remains one of his firm's top picks following the company's analyst day and fiscal 2019 guidance. The company is in "full growth mode" with its fiscal 2019 sales outlook exceeding consensus across the board, Zukin tells investors in a research note titled "They Guide High, Stock Stays Fly." The analyst reiterates an Overweight rating on the shares with a $310 price target.
MSFT Microsoft
$105.00

-1.47 (-1.38%)

11/07/18
MAXM
11/07/18
NO CHANGE
Target $127
MAXM
Hold
Tableau price target raised to $127 from $107 at Maxim
Maxim analyst Nehal Chokshi raised his price target on Tableau (DATA) to $127 after its "solid" Q3 results that saw implied billings accelerate to 31% annualized growth in spite of the headwinds coming "from ongoing rapid transition to subscription model". The analyst also keeps his Hold rating on Tableau, stating that the December quarter outlook implies a billings deceleration to 17% while also noting that the company is facing a "lurking" competitive threat from Microsoft (MSFT).
11/13/18
SUSQ
11/13/18
UPGRADE
Target $95
SUSQ
Positive
Xilinx upgraded to Positive with $95 price target at Susquehanna
As reported previously, Susquehanna analyst Christopher Rolland upgraded Xilinx (XLNX) to Positive from Neutral. The analyst likes the company's A.I. inference opportunity and its strong showing with Alveo. He said the early read on Alveo pricing puts it in the ballpark with Nvidia's (NVDA) T4. He is also encouraged that Microsoft (MSFT) may begin to dual source DC FPGAs, which was an opportunity that he thought had previously been locked up by Altera. Rolland raised his price target to $95 from $82 on Xilinx shares.
11/12/18
LBOW
11/12/18
NO CHANGE
LBOW
Neutral
Earnings commentary shows 'ample evidence' of hyperscale caution, says Longbow
Longbow analyst Joe Wittine said that Microsoft (MSFT) signaled along with its earnings report that growth in investments would moderate, Amazon (AMZN) highlighted a focus on driving data center efficiencies, Alphabet (GOOGL) is understood to be eh "the largest driver" of Seagate's (STX) lowered outlook and Apple (AAPL) expects FY19 capex of $14B, down from this year's $16.7B. Wittine sees all of this as "ample evidence of increased caution in the hyperscale investment cycle," which leads his to believe his Neutral ratings on both Seagate and Western Digital (WDC) remain appropriate.
10/29/18
OPCO
10/29/18
NO CHANGE
OPCO
IBM/Red Hat may look to partner much more with Google, says Oppenheimer
Oppenheimer analyst Timothy Horan notes that IBM (IBM) and Red Hat (RHT) have lagged leaders such as Microsoft (MSFT), Amazon (AMZN), Google (GOOG; GOOGL) in the cloud. By merging, they are trying to improve their cloud position and Horan sees them looking to use the disruptive Container/Kubernetes to create a new hybrid cloud platform. Given how far behind they are in infrastructure, the analyst believes they may look to partner much more with Google, which is a threat to Microsoft more so than AWS. While Horan thinks the deal does open up an opportunity for a combined IBM/Red Hat to enter the market with a new service, they still have a long way to go before they can compete with Microsoft and Amazon in cloud.
GOOG Alphabet
$1,043.53

7.2 (0.69%)

11/13/18
BARD
11/13/18
NO CHANGE
BARD
Amazon selection of East Coast corridor for HQs makes sense, says Baird
Baird analyst Colin Sebastian noted that he'd predicted last October that Washington DC was "a slight favorite in the HQ2 sweepstakes," and he believes Amazon's (AMZN) selection of a second headquarters divided between Long Island City, NY and Arlington, Virginia "makes logical sense." He sees the primary motivation for the HQ split was talent availability, Sebastian added. The analyst maintains an Outperform rating and $2,100 price target on Amazon shares. Adding that "it did not receive the headlines of the HQ2 bidding process," Google (GOOGL) is said by the Wall Street Journal to be acquiring space for an additional 12-14K employees in New York, Sebastian also noted.
10/29/18
OPCO
10/29/18
NO CHANGE
Target $1435
OPCO
Outperform
Alphabet price target lowered to $1,435 from $1,450 at Oppenheimer
Oppenheimer analyst Jason Helfstein lowered his price target for Alphabet to $1,435 from $1,450, while reiterating an Outperform rating on the shares on attractive GARP characteristics. The analyst notes that while focus is on slowing revenue growth and reduced margins, results appear stable if looking at the two-year comp and focusing on Google Segment EBITDA. As TAC pressure continues to be moderate in Q4 and early 2019, Alphabet is on track for accelerating free cash flow/share growth, he contends, adding that upside from Waymo is not priced into shares.
11/14/18
LEHM
11/14/18
NO CHANGE
Target $1400
LEHM
Overweight
Barclays removes Alphabet as Top Pick, keeps Overweight rating
Barclays analyst Ross Sandler removed Alphabet (GOOGL) as his Top Pick and did not replace it with another stock. The analyst, however, keeps an Overweight rating on the shares with a $1,400 price target.
CP Canadian Pacific
$206.35

-0.94 (-0.45%)

10/05/18
10/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Outperform from Market Perform at BMO Capital with analyst Alex Arfaei citing the prospects of its LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. 2. Helmerich & Payne (HP) upgraded to Overweight from Equalweight at Capital One. 3. Canadian Pacific (CP) upgraded to Buy from Hold at TD Securities. 4. Eni SpA (E) and Equinor (EQNR) were upgraded to Buy from Neutral at BofA/Merrill. 5. Fiesta Restaurant (FRGI) upgraded to Neutral from Underweight at Piper Jaffray with analyst Nicole Miller Regan saying the company has recently reported better than expected results and sustained a return to positive same-store sales trends. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/18
STFL
10/12/18
UPGRADE
Target $244
STFL
Buy
Canadian Pacific upgraded to Buy from Hold at Stifel
Stifel analyst Michael Baudendistel upgraded Canadian Pacific to Buy while lowering his price target for the shares to $244 from $247. The analyst believes the selloff in the stock earlier this week provides "sufficient upside" for a Buy rating. Further, he says he did not fully appreciate the opportunities and strategic initiatives Canadian Pacific has in its pipeline prior to the investor day last week. These include the potential to expand capacity in key locations near terminals, the benefits of investment in new equipment such as the high-capacity grain cars, and recent operational improvements to intermodal operations, Baudendistel tells investors in a research note.
10/18/18
NATB
10/18/18
UPGRADE
NATB
Outperform
Canadian Pacific upgraded to Outperform from Sector Perform at National Bank
National Bank analyst Cameron Doerksen upgraded Canadian Pacific to Outperform from Sector Perform with a price target of CAD303.
11/09/18
GDHS
11/09/18
NO CHANGE
GDHS
Gordon Haskett says CSX flight data 'hints at' Canadian Pacific deal talks
Gordon Haskett analyst Don Bilson said in an event-driven research note that the corporate jet of CSX (CSX) was in Calgary, the home of Canadian Pacific (CP), on Wednesday, according to a service that tracks corporate jet activity. He added that "this happens to be the first time the Florida-based CSX jet has been spotted in Calgary in two years." Bilson also notes that the jets of both corporations were both seen in Chicago on October 31 and then again on November 6. While admitting he does not know if the recent visit "had any sort of strategic focus," it seems to Bilson "like a good bet" that CSX "stopped by CP while it was in town." Though "an unusual sighting is hardly confirmation that a deal is in the works" and travel data "doesn't have a very high hit rate," Bilson said the trip "hints at" possible deal-talk between the two, which have been rumored as merger candidates.
UNH UnitedHealth
$264.95

-4.49 (-1.67%)

11/14/18
MSCO
11/14/18
NO CHANGE
MSCO
Overweight
UnitedHealth will likely go as OptumHealth goes, says Morgan Stanley
Morgan Stanley analyst Zack Sopcak noted that UnitedHealth aims to achieve $100B in 2025 revenue for OptumHealth, its provider/services business. He estimates that if OptumHealth were to achieve that $100B revenue aspiration in 2025, it would contribute about 42% of revenue and about 40% of profit growth for the total company over the next seven years. Given this, he thinks "as OptumHealth goes, so will likely UnitedHealth." Sopcak, in his preview note ahead of UnitedHealth's analyst day, wrote: "If the 2010s were the decade of OptumRx, we expect the 2020s to be the decade of OptumHealth." He keeps an Overweight rating on UnitedHealth shares ahead of the analyst event on November 27.
10/31/18
EVER
10/31/18
NO CHANGE
EVER
Outperform
Gilead sales not at risk from UnitedHealth promotions, says Evercore ISI
Evercore ISI analyst Umer Raffat attributes the pullback today in shares of Gilead Sciences (GILD) to concerns over the company's HIV franchise given UnitedHealth's (UNH) promotions of cheaper alternatives. UnitedHealth (UNH) is offering a rewards plan to patients starting with HIV medications to help promote the use of lower priced drugs, Jefferies analyst Michael Yee pointed out earlier today in a research note. Raffat, however, does not see risk to Gilead's sales from the promotions. UnitedHealth's is proposing a switch to two separate tablets, which is not in the HIV guidelines today, says the analyst. He keeps an Outperform rating on Gilead shares, which are down 6% to $68.00 in afternoon trading.
10/31/18
MZHO
10/31/18
NO CHANGE
Target $94
MZHO
Buy
Mizuho says concerns over UnitedHealth program impact on Gilead seem unwarranted
Mizuho analyst Salim Syed blames UnitedHealth's (UNH) introduction of a new a program, called "My ScriptRewards," that will try to convince plan participants to take a cheaper HIV regimen in return for $500 in debit cards for the weakness in shares of Gilead (GILD). However, the analyst views the worries as unwarranted, noting that Cimduo is the "common thread" between all of the regimens that UnitedHealth's program calls out and it is an inferior drug to Gilead's Biktarvy. Biktarvy is the backbone of the number one recommended regimen according to HHS treatment guidelines, noted Syed, who keeps a Buy rating and $94 price target on Gilead shares.
10/30/18
ARGS
10/30/18
DOWNGRADE
ARGS
Hold
LabCorp downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded LabCorp (LH) to Hold from Buy after its Q3 earnings miss and a cut in FY18 guidance. The analyst notes that the company is faced with pressure from "lower lab testing payment rates mandated by the Protecting Access to Medicaid Act of 2014" along with business disruptions and the impact of acquisitions which resulted in lowers margins for the quarter. Hellweg further cites LabCorp's loss of "status as the exclusive national provider of laboratory services to UnitedHealthcare (UNH)" to rival Quest Diagnostics (DGX). In spite of these short-term challenges, the analyst also maintains a positive outlook for LabCorp on a long-term basis, adding that he would "consider an upgrade if the stock stabilized at the support level of $147 per share."
CSX CSX
$70.48

0.17 (0.24%)

10/18/18
ARGS
10/18/18
NO CHANGE
Target $84
ARGS
Buy
CSX price target raised to $84 from $79 at Argus
Argus analyst John Eade raised his price target on CSX to $84 and kept his Buy rating after its Q3 results, saying the company's earnings were "sharply higher". The analyst further notes that while the stock price has outperformed the broader market, he sees more gains ahead, as improving broader economic environment is boosting volumes for goods and commodities. Eade adds that CSX earnings saw an added tailwind from lower tax rates, while the management's recent dividend increase and stock buyback signals its confidence in the company's value.
10/17/18
LOOP
10/17/18
NO CHANGE
Target $85
LOOP
Buy
CSX price target raised to $85 from $78 at Loop Capital
Loop Capital analyst Rick Paterson raised his price target on CSX to $85 and kept his Buy rating after its Q3 earnings beat, also saying that the company is closing in on its 60% operating ratio target "sooner than everyone". The analyst further contends that while CSX had "very easy comps" in the quarter since Q3 of 2017 was when it "blew up the network during the merchandise operating restructure", he believes that the company has the best financial momentum of any Class I rail in North America.
10/17/18
RBCM
10/17/18
NO CHANGE
Target $84
RBCM
Outperform
CSX price target raised to $84 from $80 at RBC Capital
RBC Capital analyst Walter Spracklin raised his price target on CSX and kept his Outperform rating after its "strong" Q3 earnings that suggested even more positive results to come. The analyst maintains that the benefits of the company's Precision Scheduled Railroading model are coming in faster and with greater impact than previously expected, as its operating ratio improved by an "impressive" 960bps from last year. Spracklin also believes that the "improved service offering" cited by the CSX management and its investment in Intermodal should yield continued positive revenue trends in 2019.
FLT FleetCor
$190.96

-3.61 (-1.86%)

11/14/18
LEHM
11/14/18
INITIATION
Target $245
LEHM
Overweight
FleetCor initiated with an Overweight at Barclays
Barclays analyst Ramsey El-Assal initiated FleetCor with an Overweight and $245 price target.
09/27/18
DBAB
09/27/18
NO CHANGE
DBAB
Buy
FleetCor could be acquirer of Western Union's B2B business, says Deutsche Bank
Bloomberg yesterday reported that Western Union (WU) is working with an adviser to potentially sell its business-to-business cross-border payments business, and that the unit could fetch $500M. Deutsche Bank analyst Ashish Sabadra believes FleetCor (FLT) could be a potential acquirer given the synergies with its Cambridge B2B cross-border payments. The analyst estimates an acquisition could be $1 accretive to earnings per share 12-18 months post acquisition close, depending on the terms of a deal and the margin potential. More importantly, the deal would significantly enhance FleetCor's market positioning in B2B cross-border payments, Sabadra tells investors in a research note. The analyst thinks a potential accretive acquisition could provide upside to 2019 estimates. He keeps a Buy rating on FleetCor.
09/06/18
DBAB
09/06/18
NO CHANGE
Target $25
DBAB
Buy
Travelport should sell eNett in near future, says Deutsche Bank
eNett could be valued at $1B and Travelport (TVPT) could use the proceeds from a divestiture for an accelerated share repurchase or potentially lower the equity required to take the company private, Deutsche Bank analyst Ashish Sabadra tells investors in a research note. The analyst believes Travelport is not being valued on a sum-of-the-parts basis and that it is not given credit for the accelerated growth in eNett. Given the "rich valuation for high-growth payment assets," Travelport should sell eNett in the near future, Sabadra contends. The analyst believes an acquisition of eNett could potentially complement Wex's (WEX) Travel and Corporate payments offering and could also be synergistic with Fleetcor's (FLT) corporate payment business. Sabadra has a Buy rating on Travelport with a $25 price target.
MLI Mueller Industries
$24.82

-0.07 (-0.28%)

05/18/18
BOSC
05/18/18
INITIATION
BOSC
Neutral
Mueller Industries initiated with a Neutral at Boenning & Scattergood
05/18/18
BOSC
05/18/18
INITIATION
BOSC
Neutral
Mueller Industries initiated with a Neutral at Boenning & Scattergood
Boenning & Scattergood analyst Ryan Connors initiated Mueller Industries with a Neutral citing balanced risk/reward.
AMZN Amazon.com
$1,599.16

-32.52 (-1.99%)

11/14/18
EVER
11/14/18
NO CHANGE
Target $1990
EVER
Outperform
Amazon's AWS operating income estimates likely conservative, says Evercore ISI
Evercore ISI analyst Anthony DiClemente kept his Outperform rating and $1,990 price target on Amazon.com, saying his deeper analysis of the company's AWS business earnings power over the longer term suggests that the consensus is "likely too conservative". The analyst states that his "dynamic model" indicates a pathway of 35% or greater operating margins by 2022 under "bullish, but still undemanding assumptions." DiClemente adds that the Street is giving Amazon "little credit for ongoing efficiency gains", only calling for about 100bps in operating margin expansion between 2018 and 2021.
11/13/18
LOOP
11/13/18
NO CHANGE
LOOP
Amazon.com HQ2 locations 'make perfect sense' to Loop Capital
Loop Capital analyst Anthony Chukumba, who has a Buy rating and $2,200 price target on Amazon shares, was not surprised by Amazon's decision to split HQ2 between New York City and Northern Virginia, saying it "made perfect sense." The analyst noted that Amazon is eligible to receive nearly $2.1B in combined tax credits and cash grants, which likely played an important role in their decision. He also noted that Amazon having a local headquarters in Norther Virginia "further cements Amazon as the frontrunner for the Department of Defense's $10B Joint Enterprise Defense Infrastructure cloud computing contract."
ATVI Activision Blizzard
$51.61

-0.93 (-1.77%)

11/09/18
STFL
11/09/18
NO CHANGE
Target $78
STFL
Buy
Activision Blizzard Q3 report had more negatives than positives, says Stifel
Stifel analyst Drew Crum said Activision Blizzard reported Q3 results he would call mixed, but "featuring more negatives than positives." Blizzard margins "seemed low" and FY18 guidance being left unchanged places heavy dependence on the holiday period, Crum tells investors in a post-earnings note. He currently has a Buy rating on Activision Blizzard shares with a $78 target price, but noted that he is in the process of updating his game model.
11/09/18
WEDB
11/09/18
NO CHANGE
Target $81
WEDB
Outperform
Activision Blizzard price target cut to $81 from $100 at Wedbush
Wedbush analyst Michael Pachter maintained an Outperform rating on Activision Blizzard but cut his price target to $81 from $100 after the company reported Q3 results roughly in line with expectations. In a research note to investors, Pachter said that despite the quarter, management did not pass through any of the Q3 upside to the full year guidance. Activision Blizzard, which is on the firm's Best Ideas List, could deliver outsized earnings growth by optimizing King's untapped ad opportunity and monetizing its Overwatch League, he adds.
11/09/18
MSCO
11/09/18
NO CHANGE
Target $72
MSCO
Overweight
Activision Blizzard price target lowered to $72 from $80 at Morgan Stanley
Morgan Stanley analyst Brian Nowak lowered his price target on Activision Blizzard shares to $72 from $80, stating that the company's choice not to pass through its Q3 beat to full-year guidance despite strong performance from "Call of Duty" speaks to the challenges facing core franchises such as Destiny, Overwatch and Hearthstone. Activision Blizzard now has fewer near-term outperforming properties than it has over the past two years, which speaks to recent execution issues, particularly at Blizzard, Nowak tells investors. However, he remains positive on the company's pipeline and "call options" such King advertising and esports and keeps an Overweight rating on Activision Blizzard shares.
11/09/18
JEFF
11/09/18
NO CHANGE
Target $85
JEFF
Buy
Activision full year estimates still have 'significant' upside, says Jefferies
Activision Blizzard did not flow it Q3 beat through to full-year guidance, implicitly taking down its Q4 outlook despite releasing two hit games in October with Call of Duty Black Ops 4 and Candy Crush Friends, Jefferies analyst Timothy O'Shea tells investors in a post-earnings research note. The analyst lowered his price target for the shares to $85 from $90 but keeps a Buy rating on the name. He still sees "significant upside" to full year earnings estimates.
IQV Iqvia
$117.33

-2.305 (-1.93%)

10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
10/22/18
PIPR
10/22/18
NO CHANGE
Target $131
PIPR
Neutral
Iqvia price target raised to $131 from $97 at Piper Jaffray
Piper Jaffray analyst Sean Wieland raised his price target on Iqvia (IQV) to $131 after its Q3 earnings beat, saying that in spite of the FX and ASC606 accounting-related headwinds, the company also posted in-line revenues. The analyst cited cost containment supporting margin upside along with a "raise on profitability metrics". Wieland is also positive on Iqvia expanding its partnership with Salesforce (CRM) which is "designed to provide technology to make clinical trials more efficient". The analyst keeps his Neutral rating, adding that his new price target is also based on the methodology transitioning to a PE multiple from Enterprise Value / EBITDA one to reflect the company's buyback program.
10/23/18
LEHM
10/23/18
NO CHANGE
Target $140
LEHM
Overweight
Iqvia price target raised to $140 from $130 at Barclays
Barclays analyst Jack Meehan raised his price target for Iqvia to $140 and reiterates an Overweight rating on the shares following yesterday's "solid" quarter. Despite the "muted" stock reaction for following earnings, there were "several encouraging leading indicators" with the Q3 results that bode well for growth heading into 2019, Meehan tells investors in a research note.
10/23/18
RBCM
10/23/18
NO CHANGE
Target $137
RBCM
Outperform
Iqvia price target raised to $137 from $129 at RBC Capital
RBC Capital analyst George Hill raised his price target on Iqvia to $137 and kept his Outperform rating after its Q3 earnings came in at the high end of guidance with higher outlook for earnings expected in FY18. The analyst adds that the most encouraging development was the management's maintained view of the company's next-gen clinical trials solution selling well as well as its expected R&D revenue growth closing the "gap with bookings" by the end of 2019.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMED

Ra Medical Systems

$1.87

-0.055 (-2.86%)

16:50
08/23/19
08/23
16:50
08/23/19
16:50
Hot Stocks
Ra Medical Systems discloses NYSE notice related to 10-Q filing delay »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$35.73

-0.81 (-2.22%)

16:47
08/23/19
08/23
16:47
08/23/19
16:47
Syndicate
Breaking Syndicate news story on Pembina Pipeline »

Pembina Pipeline files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

APEN

Apollo Endosurgery

$3.50

(0.00%)

16:44
08/23/19
08/23
16:44
08/23/19
16:44
Syndicate
Breaking Syndicate news story on Apollo Endosurgery »

Apollo Endosurgery files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
08/23/19
08/23
16:40
08/23/19
16:40
General news
Fed's Clarida said the global economy has worsened »

Fed's Clarida said…

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.